Browse Trials
Find Breast Cancer Clinical Trials That Are Right For You
The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.
Use the search box and filters to find a trial that’s right for you.
Currently viewing trials
(Last updated: March 18, 2023)
Brain Mets
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Leptomeningeal Disease
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Activities
Complementary and Alternative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Screening
Support/Education
Surveys/Interviews/Registries
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
Click here to view online studies and trials that do not require site visits
NEAREST SITE: 3 miles
Curebase
San Francisco,CA
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT04510129
Collecting Tumor Samples to Develop a Test to Predict Response to Treatment
Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OncoPrism™ is a test that helps providers predict response to immunotherapy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04510129' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cofactorgenomics.com/technology/' target='_blank'>Cofactor Genomics: OncoPrism™ Test</a> </li></ul>
NEAREST SITE: 7 miles
xCures
Oakland,CA
VISITS: Coincides with routine care
PHASE: NA
NCT ID: NCT05461430
Malignant Fluid Test to Predict Response to Treatment for Breast Cancer
Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> Additional malignant fluid will be collected as part of a standard of care procedure.</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Malignant fluid is the build up of fluid and cancer cells in your body.</li> <li class="seamTextUnorderedListItem">A cancer cell's mass response (weight change) indicates when a cancer cell begins responding to a drug before it dies.</li> <li class="seamTextUnorderedListItem">The results from the mass response test may be used by your doctor to choose your next treatment(s).</li> <li class="seamTextUnorderedListItem">Additional malignant fluid will be collected as part of a standard of care procedure.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05461430' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.travera.com/clinical-study-summary' target='_blank'>Travera Trial Information Page: TRV-003</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.travera.com/technology' target='_blank'>Travera: Mass Response Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.thoracic.org/patients/patient-resources/resources/malignant-pleural-effusions.pdf' target='_blank'>American Thoracic Society: Malignant Fluid</a> </li></ul>
NEAREST SITE: 28 miles
Stanford Hospital and Clinics
Palo Alto,CA
VISITS: 1 visit that coincides with surgery
PHASE: II
NCT ID: NCT04440982
Detection of Cancer Cells During Lumpectomy in Women Who Received Therapy Before Surgery
Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Patients With Breast Cancer Receiving Neoadjuvant Therapy Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups and receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: LUM Imaging System to see if cancer cells remain</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LUM015, by IV, 2 to 6 hours prior to surgery</li> <li class="seamTextUnorderedListItem">LUM imaging to decide if more breast tissue should be removed during surgery</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard Care to see if cancer cells remain</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LUM015, by IV, 2 to 6 hours prior to surgery</li> <li class="seamTextUnorderedListItem">Standard care to decide if more breast tissue should be removed during surgery</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The LUM Imaging System uses a dye, called LUM015, that is injected into your body before surgery.</li> <li class="seamTextUnorderedListItem">The LUM015 dye then attaches to cancer cells in breast tissue. This can help the surgeon determine if cancer cells remain in the tumor bed after the DCIS or tumor has been removed. If cancer cells remain, your surgeon will remove more tissue.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04440982' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/surgery/assessing-margins/' target='_blank'>Susan G. Komen: Assessing Margins after Breast Surgery</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.lumicell.com/product-technology/technology-overview.php' target='_blank'>Lumicell Medical Device Information Page: Lumicell System</a> </li></ul>
NEAREST SITE: 28 miles
Kaiser Permanente - Northern California
Vallejo,CA
VISITS: Please contact research site
PHASE: NA
NCT ID: NCT03061305
Molecular Profiling to Select Treatment for Advanced Breast Cancer
Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection (STRATA) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> Molecular profiling will be done on your tumor sample at no cost.</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A sample of your tumor will be tested for certain mutations and biomarkers. </li> <li class="seamTextUnorderedListItem">Your doctor will be told if there are treatments or clinical trials available for people with the mutations or biomarkers found in your tumor. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03061305' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/broad-molecular-profiling-tests' target='_blank'>Breastcancer.org: Broad Molecular Profiling Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/research/octr/our-research/strata-trial' target='_blank'>UNC Lineberger Comprehensive Cancer Center: Study website</a> </li></ul>
NEAREST SITE: 252 miles
Sansum Clinic - Ridley-Tree Cancer Center (Solvang)
Solvang,CA
VISITS: Coincides with routine care
PHASE: NA
NCT ID: NCT04875351
Breast Cancer Index (BCI) Registry for Women with Stage I-III HR+ Breast Cancer
Breast Cancer Index (BCI) Registry Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast Cancer Index (BCI) tumor test</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The information collected by the Breast Cancer Index (BCI) test will help your doctor determine if you should receive 5 additional years of hormone therapy based on your risk of recurrence.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04875351' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancerindex.com/' target='_blank'>Biotheranostics Test Information Page: Breast Cancer Index Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-cancer-index-test' target='_blank'>Breastcancer.org: Breast Cancer Index Test</a> </li></ul>
NEAREST SITE: 339 miles
Providence Saint John's Health Center
Santa Monica,CA
VISITS: 1 day
PHASE: NA
NCT ID: NCT05068726
PET/CT Scan to Determine Next Treatment for Metastatic ER+, HER2- Breast Cancer
Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fluoroestradiol F18 (18F FES, Cerianna™), by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaire, 3 times within 1.5 years</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your doctor will use the results of your PET/CT scan to determine your next treatment.</li> <li class="seamTextUnorderedListItem">Fluoroestradiol F18 (18F FES, Cerianna™) is a tracer that is used to visualize the estrogen receptor (expressed by some cancer cells) during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer to look for signs of disease, including cancer.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ and 2+.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05068726' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.gehealthcare.com/products/nuclear-imaging-agents/cerianna' target='_blank'>GE Healthcare: Fluoroestradiol F18 (18F FES, Cerianna™)</a> </li></ul>
NEAREST SITE: 340 miles
Valkyrie Clinical Trials
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT05414123
CNSide Test to Monitor Treatment Response and Make Treatment Decisions in People with Leptomeningeal Metastases
A Longitudinal Therapy Response Monitoring Study in Subjects With Leptomeningeal Metastases Using CNSide (CSF Tumor Cells) Compared to Standard of Care (CSF Cytology, Clinical Evaluation, and Imaging). Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid that surrounds your brain and spinal cord. CSF is typically collected during a procedure called a lumbar puncture, also known as a spinal tap.</li> <li class="seamTextUnorderedListItem">The CNSide test can detect and measure tumor cells in CSF.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05414123' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://biocept.com/cnside-assay/' target='_blank'>Biocept: CNSide Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/lumbar-puncture/about/pac-20394631#:~:text=A%20lumbar%20puncture%20(spinal%20tap)%20is%20a%20test%20used%20to,a%20sample%20of%20cerebrospinal%20fluid.' target='_blank'>Mayo Clinic: Lumbar Puncture</a> </li></ul>
NEAREST SITE: 602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City,UT
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT04450706
Biopsy to Select Treatment for Metastatic HER2-Negative Breast Cancer
FORESEE: Functional Precision Oncology for Metastatic Breast Cancer: a Feasibility Trial Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy to collect tumor tissue</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor tissue collected during the biopsy will be used for genomic testing and drug screening.</li> <li class="seamTextUnorderedListItem">Genomic testing identifies DNA in your tumor cells.</li> <li class="seamTextUnorderedListItem">Drug screening tests the response of your tumor cells to potential treatments.</li> <li class="seamTextUnorderedListItem">The results from the genomic testing and drug screening may be used by your doctor to choose your next treatment(s).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04450706' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancercenter.com/treatment-options/precision-medicine/advanced-genomic-testing' target='_blank'>Cancer Treatment Centers of America: Genomic Testing</a> </li></ul>
NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City,UT
VISITS: 1 visit
PHASE: II
NCT ID: NCT04252859
Using a PET/CT Scan to Find Lobular Breast Cancer Cells Before Surgery for Stage I-IV Lobular Breast Cancer
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan using (18F) FES tracer, 1 time</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer. A tracer looks for and attaches to cancer cells.</li> <li class="seamTextUnorderedListItem">Lobular breast cancer is a subtype of breast cancer. It is estimated that 10 to 15 percent of all breast cancers are lobular. </li> <li class="seamTextUnorderedListItem">Standard of care PET/CT scans that use a FDG tracer generally do not find lobular breast cancer tumors as well as they find ductal breast cancer tumors and PET/CT scans are not usually given to people with stage I-II lobular breast cancer. </li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called (18F)Fluoroestradiol (FES). Researchers believe this tracer is better at locating and attaching to lobular cancer cells than the standard of care tracer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04252859' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://lobularbreastcancer.org/imagingilc/' target='_blank'>Lobular Breast Cancer Alliance: Imaging and Lobular Breast Cancer</a> </li></ul>
NEAREST SITE: 1539 miles
Mayo Clinic Health System Mankato
Mankato,MN
VISITS: At least 2 visits
PHASE: NA
NCT ID: NCT05662345
Circulating Tumor Cells Test to Make Treatment Decisions for Metastatic Breast Cancer
ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample for CELLSEARCH® Circulating Tumor Cell Test</li> </ul> <p class="seamTextPara"> followed within 1.5 years by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging scans, at least 1 time</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li> <li class="seamTextUnorderedListItem">The CELLSEARCH® Circulating Tumor Cell Test can detect CTCs in your blood to help your doctor make treatment decisions and determine your response to treatment.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05662345' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cellsearchctc.com/about-cellsearch/what-is-cellsearch-ctc-test' target='_blank'>Menarini Silicon Biosystems: CELLSEARCH® Circulating Tumor Cell Test</a> </li></ul>
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: 1 visit
PHASE: NA
NCT ID: NCT02918474
A Tool to Help Women Decide Whether to Have a Contralateral Preventative Mastectomy
Decision Making Tool for Contralateral Prophylactic Mastectomy Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will complete a questionnaire before and after using the decision support tool.</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">If you take part in this study, you will complete a questionnaire about the decision support tool.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02918474' target='_blank'>ClinicalTrials.gov</a> </li></ul>
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT02152254
Molecular Profiling-Based Targeted Therapies for Metastatic Breast Cancer (Basket Study)
A Basket Study: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> All participants will have their tumor biopsy undergo molecular profiling. Participants who have tumors with no molecular abnormality will receive an FDA-approved therapy. Participants with a molecular abnormality will then be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Targeted therapy based on molecular profiling</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physican's choice standard of care</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Patients whose tumors progress will have the option of crossing over to the other treatment arm</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Molecular profiling of a tumor may identify genetic mutations or biomarkers that suggest the tumor is likely to respond to a currently available targeted therapy. </li> <li class="seamTextUnorderedListItem">It is not known if choosing metastatic breast cancer treatment based on the tumor's molecular profile is more effective than the current standard of care. </li> <li class="seamTextUnorderedListItem">All people who enroll in this study will have molecular profiling performed on a biopsy of their tumor. </li> <li class="seamTextUnorderedListItem">If there is no mutation or biomarker found, you will receive the treatment the doctor determines is the best option. </li> <li class="seamTextUnorderedListItem">If a mutation or biomarker is found and there is an FDA-approved drug for the tumor type, you will be offered that treatment. </li> <li class="seamTextUnorderedListItem">If there is a mutation or biomarker found but no FDA-approved drug that targets it, you will be randomly assigned to either a targeted therapy or the standard of care.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">This type of study is called a basket trial. Basket trials enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: vary based on test results.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02152254' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825646/' target='_blank'>Journal Article: Molecular Profiling for Breast Cancer</a> </li></ul>
NEAREST SITE: 1678 miles
University of Wisconsin Carbone Cancer Center
Madison,WI
VISITS: 1 visit every 3 to 4 weeks, ongoing
PHASE: NA
NCT ID: NCT04174352
Imaging to Personalize Amount of Tamoxifen in Advanced, ER+, HER2- Breast Cancer With a ESR1 Mutation
A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">FES PET/CT scan, every 3 to 4 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®) is an anti-estrogen therapy used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">ESR1 mutations in breast cancer may affect how well tamoxifen works against tumor cells. </li> <li class="seamTextUnorderedListItem">Tracers are chemicals that are used to find cancer cells in the body during a PET scan. The imaging trial will use the tracer fluoroestradiol (FES)--it finds estrogen receptors in breast tumors. </li> <li class="seamTextUnorderedListItem">The FES tracer may also show how tamoxifen is affecting your tumors. Researchers may use this information to increase your dose of tamoxifen.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR1</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04174352' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/hormonal-therapy-metastatic-breast-cancer' target='_blank'>ASCO Cancer.net: Hormonal Therapy for Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen' target='_blank'>Breastcancer.org: Tamoxifen</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/more-effective-therapies-needed-for-patients-with-esr1mutated-breast-cancer' target='_blank'>Targeted Oncology: More Effective Therapies Needed For Patients With ESR1-Mutated Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.karger.com/Article/FullText/481428' target='_blank'>Journal Article: Are We Ready to Use ESR1 Mutations in Clinical Practice</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ijcem.com/files/ijcem0076055.pdf' target='_blank'>Journal Article: The Role of PET Imaging Probes for Early Monitoring the Response to Tamoxifen</a> </li></ul>
NEAREST SITE: 1761 miles
University of Wisconsin School of Medicine and Public Health
Madison,WI
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT04573231
Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer
Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-DCFPyL</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTC) test</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Prostate specific membrane antigen (PSMA) expression may correlate with resistance to anti-androgen therapies, which has been documented in prostate cancer.</li> <li class="seamTextUnorderedListItem">Evaluating PSMA expression may be used to select people most likely to benefit from anti-androgen therapies, such as bicalutamide (Casodex®), in future clinical trials.</li> <li class="seamTextUnorderedListItem">18F-DCFPyL is a tracer that is used to visualize PSMA expression during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are breast cancer cells that leave the tumor and move through the bloodstream.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PSMA, AR</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04573231' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/psma-new-target-prostate-cancer-treatment' target='_blank'>Memorial Sloan Kettering Cancer Center: PSMA</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/#:~:text=A%20circulating%20tumor%20cell%20(CTC,test%20for%20metastatic%20breast%20cancer.' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li></ul>
NEAREST SITE: 1906 miles
Clinical Site
Covington,LA
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT05697198
OmniSeq Test to Detect Biomarkers and Mutations in People with Advanced Breast Cancer
PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations Using the OmniSeq Test and Creation of a Biobank From Community Cancer Clinics in the United States to Address Disparities in Precision Medicine Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and/or tissue samples for OmniSeq Test</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The OmniSeq Test is a genomic test that detects biomarkers and mutations for many types of cancer.</li> <li class="seamTextUnorderedListItem">The OmniSeq Test may help your doctor select your treatment based on detected biomarkers and mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05697198' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://oncology.labcorp.com/cancer-care-team/test-menu/omniseq-insight' target='_blank'>Labcorp: OmniSeq Test</a> </li></ul>
NEAREST SITE: 2133 miles
Columbus Regional Research Institute, John B. Amos Cancer Center
Columbus,GA
VISITS: Coincides with routine care
PHASE: NA
NCT ID: NCT04985357
Tumor Test to Predict Response to Treatment for Stage III-IV Breast Cancer
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> Additional tumor tissue will be collected as part of a standard of care biopsy.</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A tumor cell's mass response (weight change) indicates when a tumor cell begins responding to a drug before it dies.</li> <li class="seamTextUnorderedListItem">The results from the mass response test may be used by your doctor to choose your next treatment(s).</li> <li class="seamTextUnorderedListItem">Additional tumor tissue will be collected as part of a standard of care biopsy.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04985357' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.travera.com/clinical-study-summary' target='_blank'>Travera Trial Information Page: TRV-002</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.travera.com/technology' target='_blank'>Travera: Mass Response Test</a> </li></ul>
NEAREST SITE: 2260 miles
Allegheny Health Network Cancer Institute
Pittsburgh,PA
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT02965755
Tumor Molecular Profiling by Liquid Biopsy for Choosing Treatments for Metastatic Breast Cancer
Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic profiling of your cancer using a liquid biopsy (blood test)</li> <li class="seamTextUnorderedListItem">Genetic profiling of your cancer using a tumor sample already in your medical records</li> <li class="seamTextUnorderedListItem">Possible treatment recommendations based on the results of the genetic profiling</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The information obtained from the liquid biopsy may help guide recommendations for your next treatment.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02965755' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/KomenPerspectives/Tumor-profiling-–-personalizing-treatment-for-breast-cancer.html' target='_blank'>Susan G. Komen: Tumor Profiling-Personalizing Treatment for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2017/liquid-biopsy-detects-treats-cancer' target='_blank'>NCI Cancer Currents Blog: Liquid Biopsy</a> </li></ul>
NEAREST SITE: 2385 miles
Duke University Medical Center
Durham,NC
VISITS: 1 visit
PHASE: NA
NCT ID: NCT04655573
Tissue Collection During Surgery to Determine Chemotherapy for Advanced Breast Cancer
A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove tumor and generate PDMO</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your tissue removed during surgery will be used to generate a patient derived micro-organosphere (PDMO).</li> <li class="seamTextUnorderedListItem">A PDMO is a way to test which chemotherapy will be the most effective to treat your cancer.</li> <li class="seamTextUnorderedListItem">The information obtained from the PDMO will help your doctor choose which chemotherapy you will receive.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04655573' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2022/micro-organospheres-cancer-model-treatment-response' target='_blank'>National Cancer Institute: Patient Derived Micro-Organosphere (PDMO)</a> </li></ul>
NEAREST SITE: 2406 miles
UNC Lineberger Comprehensive Cancer Center
Chapel Hill,NC
VISITS: 1 visit
PHASE: NA
NCT ID: NCT03769415
HARMONY: Using a Genomic Test to Guide Treatment Decisions for Metastatic Breast Cancer
HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PAM50 (Prosigna®) testing of your breast tumor, 1 time</li> <li class="seamTextUnorderedListItem">Results of the PAM50 test will be given to your treating doctor</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The standard of care for treating metastatic breast cancer is to make treatment decisions based on clinical subtype. </li> <li class="seamTextUnorderedListItem">Clinical subtypes include hormone-positive (ER+ and/or PR+), HER2-positive (HER2+), and triple-negative (ER-, PR-, HER2-).</li> <li class="seamTextUnorderedListItem">The PAM50 (Prosigna®) is a genomic test approved for use in some women with early-stage breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Genomic testing looks at genetic mutations within your tumor. This gives your doctor a genetic subtype of your tumor. </li> <li class="seamTextUnorderedListItem">This trial is studying whether knowing a tumor's genetic subtype will affect how doctors treat people with metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Making treatment decisions based on genetic subtypes is not the standard of care.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03769415' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/octr/our-team/' target='_blank'>Study Coordinator Information: Terri Eubanks</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/genomic-tumor-testing/' target='_blank'>Metastatic Trial Talk: Genomic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prosigna.com' target='_blank'>Veracyte Test Information Page: PAM50 (Prosigna®)</a> </li></ul>
NEAREST SITE: 2425 miles
Inova Schar Cancer Institute
Fairfax,VA
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT04965688
Genetic Testing to Determine Treatment for ER+, HER2- Metastatic Breast Cancer
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">FoundationOne and Fulgent genetic testing</li> <li class="seamTextUnorderedListItem">Drug based on genetic testing results</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">There are several approved treatments for metastatic ER+, HER2- breast cancer. Right now, doctors do not have a good way of choosing between these treatments.</li> <li class="seamTextUnorderedListItem">Researchers have developed a way to predict which treatment is best.</li> <li class="seamTextUnorderedListItem">This study is being done to test if those predictions are right and to learn more about these tumors to design better treatments in the future.</li> <li class="seamTextUnorderedListItem">You will receive a drug based on the results of your genetic testing results.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04965688' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.foundationmedicine.com/info/detail/for-patients' target='_blank'>Foundation Medicine: FoundationOne Genetic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://fulgentoncology.com/patients' target='_blank'>Fulgent: Genetic Testing</a> </li></ul>
Impact of ctDNA Information on Decision Making After Treatment
Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online survey, 1 time</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small bits of cancer cell DNA that specific tests can find in the bloodstream. The presence of ctDNA may indicate the presence of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05730010' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/identifying-use-of-ctdna-across-tumor-types' target='_blank'>Cancer Network: ctDNA in Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/genetics/understanding/testing/circulatingtumordna/' target='_blank'>MedLine Plus: What is ctDNA?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/practical-advice-on-the-use-of-ctdna-testing-in-breast-cancer' target='_blank'>OncLive: ctDNA Testing in Breast Cancer</a> </li></ul>
